The Effects of High Dose Pravastatin and Low Dose Pravastatin and Ezetimibe Combination Therapy on Lipid, Glucose Metabolism and Inflammation
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Coronary artery disease (CAD) is presently the major cause of mortality and morbidity. Anti-hyperlipidemic treatment is one of the main treatment steps in the management of CAD. Statins are the cornerstones in this treatment. Ezetimibe can be reliably used, when statins prove ineffective in treatment, or to reduce their side effects. In the present study we examined the effects of high-dose pravastatin (40 mg) and low-dose pravastatin (10 mg) + ezetimibe (10 mg) combination therapy on lipid and glucose mechanism, as well as inflammation.
This study registered 100 cases. Of the cases, 50 [57.1 ± 11.1 years (24 (48%) females and 26 (52%) males)] were administered 40 mg/day pravastatin (group 1) and 50 [53.2 ± 12.2 years (27 (54%) females and 23 (46%) males)] were administered 10 mg pravastatin + 10 mg ezetimibe (group 2).
In group 1, total cholesterol fell from 231.1 ± 83.5 mg/dl to 211.3 ± 37.2 mg/dl (p = 0.03), triglyceride from 243.5 ± 96.8 mg/dl to 190.9 ± 55.2 mg/dl (p = 0.003), and LDL cholesterol from 165.7 ± 29.7 mg/dl to 133.4 ± 26.6 mg/dl (p = 0.02). In group 2, total cholesterol dropped from 250.9 ± 51.8 mg/dl to 187.9 ± 34.9 mg/dl (p = 0.001), triglyceride from 270.3 ± 158.9 mg/dl to 154.6 ± 60.7 mg/dl (p = 0.001), and LDL cholesterol from 158.1 ± 47.5 mg/dl to 116.9 ± 26.4 mg/dl (p = 0.001). Insulin resistance decreased from 4.05 ± 2.31 to 3.16 ± 1.90 (p = 0.07) in group 1 and from 2.96 ± 1.50 to 2.05 ± 0.55 (p = 0.009) in group 2. High sensitive C-reactive protein fell from 6.69 ± 6.11 mg/l to 3.02 ± 1.70 mg/l (p = 0.01) in group 1 and from 6.36 ± 2.06 mg/l to 2.68 ± 1.69 mg/l (p = 0.001) in group 2.
Both therapy regimes are effective. However, we found that low-dose pravastatin and ezetimibe combination therapy is more effective than high-dose pravastatin therapy on lipid metabolism, glucose metabolism and inflammation.
- Murray, C. J., and A. D. Lopez. 1997. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 349:1269–1276. CrossRef
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2486–2497. CrossRef
- Kastelein, J., and M. J. van Dam. 2001. A new role for combination therapy in lipid management. Br. J. Cardiol. 8:639–653.
- Pearson, T. A., I. Laurora, H. Chu, and S. Kafonek. 2000. The lipid treatment assessment project (L–TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 28(160):459–467. CrossRef
- van Heek, M, C. F. France, D. S. Compton, R. L. Mcleod, N. P. Yumibe, K. B. Alton, E. J. Sybertz, and H. R. Davis, Jr. 1997. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther. 283:157–163.
- van Heek, M., C. Farley, D. S. Compton, L. Hoos, and H. R. Davis. 2000. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. 129:1748–1754. CrossRef
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). 1993. JAMA 269:3015–3023. CrossRef
- Haffner, S. M., H. Miettinen, and M. P. Stern. 1997. The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087–1092. CrossRef
- Anonymous. 2001. Statin therapy—what now? Drug Ther. Bull. 39:17–21. CrossRef
- Libby, P. 2002. Atherosclerosis: the new view. Sci. Am. 286(5):46–55.
- Pyorala, K., and D. Wood. 1998. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. Eur. Heart. J. 19:1434–1503. CrossRef
- Primatesta, P., and N. R. Poulter. 2000. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 321:1322–1325. CrossRef
- Leitersdorf, E. 2002. Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Int. J. Clin. Pract. 56(2):116–119.
- Brown, W. V. 2001. Novel approaches to lipid lowering: what is on the horizon? Am. J. Cardiol. 87(5A):23B–27B. CrossRef
- van Heek, M, C. Farley, D. S. Compton, L. Hoos, and H. R. Davis. 2001. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol. 134(2):409–417. CrossRef
- Miettinen, T. A. 2001. Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy. Drug Focus 55:710–716.
- Davis, H. R. Jr, D. S. Compton, L. Hoos, and G. Tetzloff. 2001. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in Apo E knockout mice. Arterioscler. Thromb. Vasc. Biol. 21:2032–2038. CrossRef
- Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop, and Packard C. J. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1301–1307. CrossRef
- Reaven, G. 1988. The Banting Lecture: the role of insulin resistance in human disease. Diabetes 37:1596–1607.
- Ginsberg, H. N. 2003. Treatment for patients with the metabolic syndrome. Am. J. Cardiol. 91:29E–39E. CrossRef
- Fontbonne, A. 1994. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 37:953–955. CrossRef
- Reaven, G. M., and A. Laws. 1994. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease. Diabetologia 37:948–952. CrossRef
- Despres, J. P., B. Lamarche, P. Mauriège, B. Cantin, G. R. Dagenais, S. Moorjani, and P. J. Lupien. 1996. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334:952–957. CrossRef
- Paolisso, G., A. Gambardella, D. Galzerano, A. D’Amore, V. Balbi, M. Varricchio, and F. D’Onofrio. 1993. Metabolic features of patients with and without coronary heart disease but with superimposable cluster of cardiovascular risk factors. Coron. Artery Dis. 4:1085–1091. CrossRef
- Bressler, P., S. R. Bailey, M. Matsuda, and R. A. DeFronzo. 1996. Insulin resistance and coronary artery disease. Diabetologia. 39:1345–50 (Erratum in: Diabetologia 1997;40:366). CrossRef
- Grundy, S. M., B. Howard, S. Smith, Jr, R. Eckel, R. Redberg, and R. O. Bonow. 2002. Prevention Conference, VI: Diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105:2231–2239. CrossRef
- Reaven, G. 1994. Syndrome X: 6 years later. J. Intern. Med. Suppl. 736:13–22.
- Ridker, P. M., C. H. Hennekens, J. E. Buring, and N. Rifai. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:836–843. CrossRef
- Rifai, L., Rose, J. E. Buring, and N. R. Cook. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347:1557–1565. CrossRef
- Haverkate, F., S. G. Thompson, S. D. Pyke, J. R. Gallimore, and M. B. Pepys. 1997. Production of C-reactive protein and risk of coronary events in stable and unstable angina European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349(9050):426–462. CrossRef
- Pietila, K. O., A. P. Harmoinen, J. Jokiniitty, and A. I. Pasternack. 1996. Serum creactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur. Heart. J. 17(9):1345–1349.
- Ridker, P. M., N. Rifai, M. A. Pfeffer, F. M. Sacks, L. A. Moye, and S. Goldman. 1998. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839–844.
- Ridker, P. M., N. Rifai, M. Clearfield, J. R. Downs, S. E. Weis, J. S. Miles, and A. M. Gotto, Jr. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. 2001. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344:1959–1965. CrossRef
- Albert, M. A., E. Danielson, N. Rifai, and P. M. Ridker. 2001. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286:64–70. CrossRef
- Sager, P. T., L. Melani, L. Lipka, J. Strony, B. Yang, R. Suresh, and E. Veltri. 2003. Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol. 92:1414–1418. CrossRef
- The Effects of High Dose Pravastatin and Low Dose Pravastatin and Ezetimibe Combination Therapy on Lipid, Glucose Metabolism and Inflammation
Volume 30, Issue 6 , pp 230-235
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- insulin resistance
- Industry Sectors